GLP-1 Dosage: How Much to Take, When & How

GLP-1 Dosage: How Much to Take, When & How

Overview

GLP-1 (Glucagon-Like Peptide-1) receptor agonists are synthetic peptide compounds that mimic the action of endogenous incretin hormones. Common pharmaceutical analogs include semaglutide, liraglutide, and tirzepatide. As a research peptide, native GLP-1(7-36) amide and GLP-1(7-37) are studied for their effects on glucose regulation, appetite suppression, and metabolic health.

GLP-1 works by binding to GLP-1 receptors throughout the body, triggering insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite signals in the brain. The practical result: improved blood sugar control, reduced food intake, and consistent fat loss.

Cost: $40–$120 per month, making GLP-1 one of the more affordable peptide interventions for metabolic health and body composition.

Standard Dosing Protocol

Recommended Dosage Range

Injectable GLP-1 (standard protocol):

• 100–300 mcg once or twice daily via subcutaneous injection
• Most clinical applications use 0.6 mg to 2.4 mg weekly (in long-acting formulations like semaglutide)
• Typical escalation: start low, increase every 1–4 weeks to minimize gastrointestinal side effects

Frequency of Administration

• Research peptides (native GLP-1): typically dosed once or twice daily
• Pharmaceutical analogs (semaglutide, liraglutide): once weekly (semaglutide) or once daily (liraglutide)
• Tirzepatide: once weekly

Starting Dose Rationale

Begin at the lowest effective dose (0.25–0.6 mg or 25–100 mcg) to allow your body to adapt and minimize nausea, vomiting, and gastrointestinal distress—the most common side effects in the first 2–4 weeks of use.

Escalate dose every 1–4 weeks based on:

• Tolerance to gastrointestinal effects
• Appetite suppression adequacy
• Individual response to the compound

Dosing by Goal

Different objectives may warrant different dose levels and administration strategies.

Fat Loss & Body Composition

Effective dose range: 1.2–2.4 mg weekly (semaglutide) or 100–300 mcg daily (research peptides)

Clinical evidence: Semaglutide at 2.4 mg weekly produced 14.9% body weight loss over 68 weeks, with 86.4% of participants achieving ≥5% weight loss versus 31.5% in placebo. Pooled meta-analyses of 19–22 trials show GLP-1 agonists reduce fat mass by 2.25–2.95 kg and visceral fat by 14.61 cm² compared to controls.

Practical approach:

• Start at 0.6 mg weekly and titrate by 0.6 mg increments every 4 weeks
• Target 2.0–2.4 mg weekly for maximum fat loss
• Combine with resistance training and adequate protein (to preserve lean mass, since GLP-1 causes ~0.86–1.02 kg lean mass loss per ~4 kg total weight loss)

Joint Health & Osteoarthritis

Effective dose range: 2.0–2.4 mg weekly (semaglutide)

Clinical evidence: Semaglutide 2.4 mg reduced knee pain scores (WOMAC) by 34–36 points versus 22 points for placebo over 68 weeks. Mean weight loss of 15.2% accompanied pain relief, suggesting both weight loss-dependent and weight loss-independent mechanisms.

Practical approach:

• Use the same titration schedule as fat loss (0.6 mg → 2.4 mg weekly)
• Allow 8–12 weeks at the target dose to assess joint pain improvement
• Combine with resistance training and collagen supplementation for synergistic benefit

Cardiovascular & Metabolic Health

Effective dose range: 1.0–2.4 mg weekly (semaglutide); 1.8–3.0 mg daily (liraglutide)

Clinical evidence: Meta-analysis of 15 RCTs in obese individuals shows GLP-1 agonists reduce systolic blood pressure by 4.13 mmHg, diastolic by 1.39 mmHg, triglycerides (SMD −0.99), and total cholesterol (SMD −0.73). Anti-inflammatory effects include reductions in CRP (SMD −0.63), TNF-α (SMD −0.92), IL-6 (SMD −0.76), and IL-1β (SMD −3.89).

Practical approach:

• Start at 0.6 mg weekly; titrate to 1.5–2.4 mg weekly
• Monitor blood pressure and lipids every 4–8 weeks
• Continue for ≥12 weeks to observe stable reductions in inflammatory markers

Sleep Apnea (OSA)

Effective dose range: 10–15 mg weekly (tirzepatide); 2.0–2.4 mg weekly (semaglutide)

Clinical evidence: Tirzepatide reduced apnea-hypopnea index (AHI) by 25.3 events per hour at 52 weeks. Meta-analysis of 6 studies shows GLP-1 agents decrease AHI by 9.48 events/hour with concurrent weight loss of 10.99 kg.

Practical approach:

• Titrate to therapeutic dose (2.0–2.4 mg semaglutide or 10–15 mg tirzepatide weekly)
• Expect 8–16-week timeframe for significant AHI improvement
• Monitor sleep apnea severity with home oximetry or sleep study at baseline and 12 weeks

Liver Health (MASH/NAFLD)

Effective dose range: 2.4 mg weekly (semaglutide)

Clinical evidence: Semaglutide 2.4 mg achieved MASH resolution in 62.9% of patients versus 34.3% in placebo over 72 weeks. Meta-analysis of 13 RCTs shows GLP-1 agonists achieve MASH resolution with pooled odds ratio 3.48 and improve fibrosis staging.

Practical approach:

• Titrate to 2.4 mg weekly using standard escalation (0.6 mg increments every 4 weeks)
• Maintain dose for ≥72 weeks for maximum histologic benefit
• Monitor liver enzymes and, if available, elastography or biopsy at baseline and 12–24 weeks

How to Administer

Injection Technique

Route: Subcutaneous injection only (GLP-1 is not administered orally or intravenously in standard protocols)

Administration sites:

• Abdomen (most common; rotate injection sites to avoid lipohypertrophy)
• Thigh
• Upper arm
• Buttock

Step-by-step injection:

1. Prepare injection site by cleaning with alcohol pad; allow to dry (15–30 seconds)
2. Pinch skin at injection site to create a skin fold
3. Insert needle at 45–90-degree angle
4. Inject slowly to avoid pain and tissue damage
5. Withdraw needle and apply gentle pressure with gauze or alcohol pad
6. Rotate injection sites weekly to prevent localized reactions

Frequency Timing

• Once-daily dosing: administer at the same time each day (morning or evening)
• Once-weekly dosing: pick the same day each week (e.g., Monday morning) to maintain consistency
• Twice-daily dosing: space doses 12 hours apart (e.g., 8 AM and 8 PM)

Storage

• Store in refrigerator at 36–46°F (2–8°C) before first use
• Once initiated, may remain at room temperature (up to 86°F / 30°C) for up to 28 days
• Protect from light and freezing
• Do not use if frozen or visibly discolored

Cycling & Timing

Continuous vs. Cycled Dosing

Standard approach: GLP-1 is typically administered continuously without cycling, as it has a favorable safety profile with decades of clinical data in diabetes and obesity treatment.

Exception: Some users employ "pulse dosing" (e.g., 4–8 weeks on, 1–2 weeks off) to:

• Reduce tachyphylaxis (tolerance buildup)
• Allow appetite-suppressing effects to reset
• Assess individual response to compound cessation

Evidence: No clinical trials directly compare continuous versus cycled GLP-1 dosing, so choice depends on individual tolerance and preference.

Timeline for Results

• Week 1–2: Mild nausea and appetite suppression; minimal weight loss
• Week 3–4: Gastrointestinal side effects typically peak, then decline
• Week 4–8: Noticeable appetite reduction and modest weight loss (1–2 kg)
• Week 8–12: Consistent fat loss acceleration; 2–4 kg cumulative loss
• Week 12+: Steady-state fat loss of 0.5–1 kg per week at therapeutic doses; maximal effects on inflammatory markers, blood pressure, and cardiovascular outcomes typically apparent by 12–24 weeks

When to Increase Dosage

• Escalate every 4 weeks if tolerated
• Wait until gastrointestinal side effects subside before increasing
• If severe nausea or vomiting persists, delay dose escalation by 1–2 weeks
• Do not exceed 300 mcg daily or the maximum approved dose for your chosen agent

Beginner vs. Advanced Dosing

Beginner Protocol

Goal: Minimize side effects while establishing baseline tolerance

• Week 1–4: 0.25–0.6 mg once weekly OR 25–50 mcg once daily
• Week 5–8: Increase to 0.6 mg once weekly OR 50–100 mcg once daily
• Week 9–12: Escalate to 1.2 mg once weekly OR 100–200 mcg once daily
• Week 13+: Move to therapeutic dose (1.5–2.4 mg weekly OR 200–300 mcg daily) based on tolerance and goals

Expected side effects: Mild nausea (days 1–3 post-injection), transient loose stools, early satiety

Adherence strategy: Pin injection to a recurring weekly calendar event; use phone reminders

Advanced Protocol

Goal: Rapid dose escalation for maximal fat loss and metabolic benefit

• Week 1: 0.6 mg weekly OR 100 mcg daily
• Week 2: 0.75 mg weekly OR 150 mcg daily (if tolerated)
• Week 3: 1.0 mg weekly OR 200 mcg daily
• Week 4: 1.5 mg weekly OR 250 mcg daily
• Week 5+: 2.0–2.4 mg weekly OR 300 mcg daily

Expected side effects: More pronounced nausea and diarrhea in weeks 1–3; typically resolve by week 4–6

Adherence strategy: Meal planning (small, low-fat meals) to manage GI effects; consider anti-nausea supplementation (ginger, vitamin B6) if needed

Common Dosing Mistakes

1. Starting Too High

Mistake: Beginning at therapeutic dose (2.4 mg weekly) to "save time"

Consequence: Severe nausea, vomiting, dehydration, and treatment discontinuation

Fix: Always titrate from low doses; patience during weeks 1–4 yields better long-term adherence and outcomes

2. Escalating Too Quickly

Mistake: Increasing dose every 1–2 weeks instead of every 4 weeks

Consequence: Cumulative GI side effects, poor tolerance, missed doses

Fix: Respect the 4-week escalation window; delay if nausea persists

3. Inconsistent Injection Timing

Mistake: Varying injection day by 2–3 days weekly OR forgetting doses

Consequence: Unstable appetite suppression, variable weight loss, reduced metabolic benefit

Fix: Use phone reminders and tie injection to a fixed weekly event (e.g., "every Monday at 8 AM")

4. Injecting Frozen or Discolored Compound

Mistake: Using GLP-1 that has been frozen or shows cloudiness/discoloration

Consequence: Reduced efficacy, sterility concerns, potential injection site reactions

Fix: Check appearance before each injection; discard if frozen or visibly altered

5. Neglecting Lean Mass Preservation

Mistake: Using GLP-1 for fat loss without resistance training or adequate protein

Consequence: Loss of 0.86–1.02 kg lean mass per 4 kg weight loss (meta-analysis of 22 RCTs, n=2,258)

Fix: Consume 0.8–1.0 g protein per pound of body weight and perform resistance training 3–4 times weekly to minimize lean mass loss

6. Skipping Rotating Injection Sites

Mistake: Injecting in the same location repeatedly

Consequence: Lipohypertrophy (fat thickening), bruising, reduced absorption, injection site reactions

Fix: Rotate injection sites systematically (abdomen one week, thigh the next)

GLP-1 Dosage Summary Table

Important Disclaimer

This guide is educational content only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications in most jurisdictions; research-grade peptides carry unverified purity risks and are not approved for human use outside clinical trials. Before initiating GLP-1 therapy:

• Consult a licensed healthcare provider
• Disclose any personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or pancreatitis (contraindications)
• Monitor for side effects (nausea, vomiting, diarrhea, injection site reactions)
• Do not use pharmaceutical-grade GLP-1 without a valid prescription

Individual responses vary significantly; dosing should be personalized by a qualified clinician based on your medical history, current medications, and metabolic goals.